Format

Send to

Choose Destination
Am Heart J. 2014 Jul;168(1):23-9.e2. doi: 10.1016/j.ahj.2014.03.021. Epub 2014 Apr 5.

Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.

Collaborators (199)

Holman RR, Pan CY, Hu D, Chan J, Chiasson JL, Doran Z, Ge J, Gerstein H, Huo Y, Lang Z, McMurray J, Ryden L, Schröder S, Tendera M, Tuomilehto J, Yang W, Rouleau J, Collier J, Pocock S, Standl E, Swedberg K, Weng J, Zhao D, Wang D, Petrie M, Connelly E, Jhund P, MacDonald M, Myles R, Sattar N, Fisher M, Petrie J, Sun Y, Wei Y, Xu W, Groves N, Liyanage W, Tang J, Theodorakis MJ, Bi J, Feng H, Hu R, Liu P, Wei M, Wei X, Yang X, Yin J, Zhou J, Deng L, Hu D, Hua Q, Hu T, Li H, Li H, Lu J, Ma C, Ma X, Pi L, Shi L, Wang B, Wang M, Wei G, Yang M, Yang W, Zhang L, Zhang S, Zhou Y, Lei H, Liao R, Mei X, She Q, Tan J, Xia M, Chen L, Pu X, Wang Y, Xie Q, Xiong S, Chen C, Chen J, Dong Y, Li Z, Wu C, Zhou S, Yuan Y, Zhou W, Kuang R, Wei J, Zhao Z, Zhong G, Wu L, Fang H, Li H, Kong L, Liu G, Hao Y, Wang C, Li X, Wang L, Dong P, Liu H, Liu X, Zhang S, Zhao Y, Chan J, Ozaki R, Gu Y, Liao Y, Su X, Wang D, Wang H, Yang B, Guo Y, Yang T, Han Y, Lin X, Zhao R, Bian R, Guo Y, Zhang H, Hasimu B, Jin H, Liu P, Lv K, Tao Y, Xu C, Xu B, Yang Z, Yu J, Zhang G, Hong L, Hu L, Li J, Liu B, Yang P, Han P, Jin Y, Li L, Lin H, Liu J, Li Z, Wang G, Zhang S, Luan H, Song M, Xue L, Feng J, Gao F, Hua Y, Ye J, Yuan Z, Hou Z, Li X, Qi W, Su G, Wang Y, Zhang S, Wang B, Ge J, Guo X, Gong H, Gu S, He B, Jiang Y, Jin H, Li Y, Liu Q, Lu G, Ma J, Qin Y, Wu S, Xu Y, Chen X, Tang J, Wang J, Liu D, Chen X, Tao J, Yan Y, Zhang T, Li D, Du X, Guo X, Jiang T, Li T, Li Z, Lin J, Lu C, Zhao S, Zheng S, Li K, Qui Q, Tang B, Zhou J, Zhang G, Guo T, Zhang H, Shen F, Fu G.

Author information

1
Diabetes Trials Unit, University of Oxford, Oxford, United Kingdom. Electronic address: rury.holman@dtu.ox.ac.uk.
2
Diabetes Trials Unit, University of Oxford, Oxford, United Kingdom.
3
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong.
4
CRCHUM, Department of Medicine, University of Montreal, Montreal, Canada.
5
Zhongshan Hospital, Fudan University, Shanghai, China.
6
Department of Medicine and Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
7
Department of Cardiology, Peking University First Hospital, Beijing, China.
8
Institute of Cardiovascular & Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.
9
Cardiology Unit, Karolinska University Hospital Solna, Stockholm, Sweden.
10
Bayer Healthcare, Bayer Pharma AG, Berlin, Germany.
11
3rd Division of Cardiology, Medical University of Silesia, Katowice, Poland.
12
Centre for Vascular Prevention, Danube-University Krems, Krems, Austria; Diabetes Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland; King Abdulaziz University, Jeddah, Saudi Arabia.
13
China-Japan Friendship Hospital, Beijing, China.
14
People's Hospital of Peking University, Beijing, China.
15
Department of Endocrinology, People's Liberation Army General Hospital, Beijing, China.

Abstract

Patients with cardiovascular disease and impaired glucose tolerance are at increased risk of cardiovascular events and type 2 diabetes mellitus (T2DM). Lifestyle modification or pharmacological intervention can delay progression to T2DM, but there is no clear evidence that they reduce cardiovascular risk in this population. Acarbose, an α-glucosidase inhibitor that lowers postprandial blood glucose, has been shown to reduce T2DM risk by 25%, and possibly cardiovascular risk in impaired glucose tolerance subjects without cardiovascular disease.

PMID:
24952856
DOI:
10.1016/j.ahj.2014.03.021
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center